The FDA has granted approval for DUPIXENT (dupilumab) to treat eosinophilic esophagitis (EoE) in children aged 1-11 years weighing at least 15 kg. The approval follows successful Phase III EoE KIDS trial results showing superior histological remission rates compared to placebo. This development represents a significant advancement in treating pediatric EoE, a condition affecting approximately 1 in 2,000 people.
Revolo Biotherapeutics' '1104 targets antigen-presenting cells, shifting the immune system from a pro-inflammatory to a homeostatic state, potentially inducing remission in allergic conditions.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.